Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2012, Vol. 17 ›› Issue (8): 931-939.
Previous Articles Next Articles
ZHAO Qi-jin, ZHA Wei-bin, ZHOU Fang, WU Xiao-lan, CAO Bei, ZHANG Jing-wei, WANG Guang-ji
Received:
2012-01-13
Revised:
2012-03-28
Online:
2012-08-26
Published:
2012-08-14
CLC Number:
ZHAO Qi-jin, ZHA Wei-bin, ZHOU Fang, WU Xiao-lan, CAO Bei, ZHANG Jing-wei, WANG Guang-ji. The transcriptional regulation of drug enzymes and transporters mediated by Pregnane X receptor and its significant role in multidrug resistance[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(8): 931-939.
[1] Kliewer SA, Moore JT, Wade L, et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway [J]. Cell, 1998, 92(1): 73-82. [2] Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions [J]. J Clin Invest, 1998, 102(5): 1016-1023. [3] Blumberg B, Sabbagh W Jr, Juguilon H, et al. SXR, a novel steroid and xenobiotic-sensing nuclear receptor [J]. Genes Dev, 1998, 12(20):3195-3205. [4] Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity [J]. Proc Natl Acad Sci U S A, 2001, 98(6):3369-3374. [5] Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction [J]. Proc Natl Acad Sci U S A, 1998, 95(21): 12208-12213. [6] Bauer B, Hartz AM, Fricker G, et al. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier [J]. Mol Pharmacol, 2004, 66(3): 413-419. [7] Dotzlaw H, Leygue E, Watson P, et al. The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue [J]. Clin Cancer Res, 1999, 5(8):2103-2107. [8] Chen Y, Tang Y, Wang MT, et al. Human pregnane X receptor and resistance to chemotherapy in prostate cancer [J] Cancer Res, 2007, 67(21):10361-10367. [9] Lamba V, Yasuda K, Lamba JK, et al. PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators [J]. Toxicol Appl Pharmacol, 2004, 199(3):251-265. [10] Owen A, Chandler B, Back DJ, et al. Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA [J]. Antivir Ther, 2004, 9(5):819-821. [11] Albermann N, Schmitz-Winnenthal FH, Z'Graggen K, et al. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver [J]. Biochem Pharmacol, 2005, 70(6):949-958. [12] Dubrac S, Elentner A, Ebner S, et al. Modulation of T lymphocyte function by the pregnane X receptor [J]. J Immunol, 2010, 184(6): 2949-2957. [13] Zhou C, Verma S, Blumberg B. The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism [J]. Nucl Recept Signal, 2009, 7: e001. [14] Kliewer SA, Willson TM. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor [J]. J Lipid Res, 2002, 43(3): 359-364. [15] Staudinger J, Liu Y, Madan A, et al. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor [J]. Drug Metab Dispos, 2001, 29(11): 1467-1472. [16] Marschall HU, Wagner M, Zollner G, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans [J]. Gastroenterology, 2005, 129(2): 476-485. [17] Goodwin B, Redinbo MR, Kliewer SA. Regulation of cyp3a gene transcription by the pregnane x receptor [J]. Annu Rev Pharmacol Toxicol, 2002, 42: 1-23. [18] Maglich JM, Stoltz CM, Goodwin B, et al. Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification [J]. Mol Pharmacol, 2002, 62(3): 638-646. [19] Chen C, Staudinger JL, Klaassen CD. Nuclear receptor, pregname X receptor, is required for induction of UDP-glucuronosyltranferases in mouse liver by pregnenolone-16 alpha-carbonitrile [J]. Drug Metab Dispos, 2003, 31(7): 908-915. [20] Staudinger JL, Madan A, Carol KM, et al. Regulation of drug transporter gene expression by nuclear receptors [J]. Drug Metab Dispos, 2003, 31(5): 523-527. [21] Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin [J]. J Biol Chem, 2001, 276(18): 14581-14587. [22] Kast HR, Goodwin B, Tarr PT, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor [J]. J Biol Chem, 2002, 277(4):2908-2915. [23] Masuyama H, Suwaki N, Tateishi Y, et al. The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion [J]. Mol Endocrinol, 2005, 19(5): 1170-1180. [24] Bhalla S, Ozalp C, Fang S, et al. Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1alpha. Functional implications in hepatic cholesterol and glucose metabolism [J]. J Biol Chem, 2004, 279(43): 45139-45147. [25] Li T, Chiang JY. Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression [J]. Drug Metab Dispos, 2006, 34(5): 756-764. [26] Pavek P, Cerveny L, Svecova L, et al. Examination of Glucocorticoid receptor alpha-mediated transcriptional regulation of P-glycoprotein, CYP3A4, and CYP2C9 genes in placental trophoblast cell lines [J]. Placenta, 2007, 28(10): 1004-1011. [27] Watkins RE, Wisely GB, Moore LB, et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity [J]. Science, 2001, 292(5525): 2329-2333. [28] Watkins RE, Noble SM, Redinbo MR. Structural insights into the promiscuity and function of the human pregnane X receptor [J]. Curr Opin Drug Discov Devel, 2002, 5(1): 150-158. [29] Sinz M, Kim S, Zhu Z, et al. Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions [J]. Curr Drug Metab, 2006, 7(4): 375-388. [30] Sonoda J, Chong LW, Downes M, et al. Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites [J]. Proc Natl Acad Sci U S A, 2005, 102(6): 2198-2203. [31] Ee PL, Kamalakaran S, Tonetti D, et al. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene [J]. Cancer Res, 2004, 64(4): 1247-1251. [32] Dussault I, Lin M, Hollister K, et al. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR [J]. J Biol Chem, 2001, 276(36): 33309-33312. [33] Wentworth JM, Agostini M, Love J, et al. St John's wort, a herbal antidepressant, activates the steroid X receptor [J]. J Endocrinol, 2000, 166(3): R11-16. [34] Moore LB, Goodwin B, Jones SA, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor [J]. Proc Natl Acad Sci U S A, 2000, 97(13): 7500-7502. [35] Mu Y, Zhang J, Zhang S, et al. Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats [J]. J Pharmacol Exp Ther, 2006, 316(3): 1369-1377. [36] Staudinger JL, Ding X, Lichti K. Pregnane X receptor and natural products: beyond drug-drug interactions [J]. Expert Opin Drug Metab Toxicol, 2006, 2(6): 847-857. [37] Blokzijl H, Vander Borght S, Bok LI, et al. Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels [J]. Inflamm Bowel Dis, 2007, 13(6): 710-720. [38] Buler M, Aatsinki SM, Skoumal R, et al. Energy sensing factors PGC-1alpha and SIRT1 modulate PXR expression and function [J]. Biochem Pharmacol, 2011, 82(12): 2008-2015. [39] Yang J, Luan X, Gui H, et al. Byakangelicin induces cytochrome P450 3A4 expression via transactivation of pregnane X receptors in human hepatocytes [J]. Br J Pharmacol, 2011, 162(2): 441-451. [40] Wang D, Li L, Fuhrman J, et al. The role of constitutive androstane receptor in oxazaphosphorine-mediated induction of drug-metabolizing enzymes in human hepatocytes [J]. Pharm Res, 2011, 28(8): 2034-2044. [41] Chen Y, Tang Y, Robbins GT, et al. Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor [J]. J Pharmacol Exp Ther, 2010, 334(3): 999-1008. [42] Timsit YE, Negishi M. CAR and PXR: the xenobiotic-sensing receptors [J]. Steroids, 2007, 72(3): 231-246. [43] Wada T, Gao J, Xie W. PXR and CAR in energy metabolism [J]. Trends Endocrinol Metab, 2009, 20(6): 273-279. [44] Scheer N, Ross J, Rode A, et al. A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response [J]. J Clin Invest, 2008, 118(9): 3228-3239. [45] Kumar S, Jaiswal B, Negi S, et al. Cross-talk between androgen receptor and pregnane and xenobiotic receptor reveals existence of a novel modulatory action of anti-androgenic drugs [J]. Biochem Pharmacol, 2010, 80(7): 964-976. [46] Hopkins AL. Network pharmacology: the next paradigm in drug discovery [J]. Nat Chem Biol, 2008, 4(11): 682-690. [47] Miki Y, Suzuki T, Kitada K, et al. Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma [J]. Cancer Res, 2006, 66(1): 535-542. [48] Gupta D, Venkatesh M, Wang H, et al. Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer [J]. Clin Cancer Res, 2008, 14(17): 5332-5340. [49] Masuyama H, Hiramatsu Y, Kodama J, et al. Expression and potential roles of pregnane X receptor in endometrial cancer [J]. J Clin Endocrinol Metab, 2003, 88(9): 4446-4454. [50] Masuyama H, Nakatsukasa H, Takamoto N, et al. Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells [J]. Mol Pharmacol, 2007, 72(4): 1045-1053. [51] Zhou J, Liu M, Zhai Y, et al. The antiapoptotic role of pregnane X receptor in human colon cancer cells [J]. Mol Endocrinol, 2008, 22(4): 868-880. [52] Mensah-Osman EJ, Thomas DG, Tabb MM, et al. Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines [J]. Cancer, 2007, 109(5): 957-965. [53] Raynal C, Pascussi JM, Legueline G, et al. Pregnane x Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation [J]. Molecular Cancer, 2010, 9(46). [54] Chen Y, Tang Y, Chen S, et al. Regulation of drug resistance by human pregnane X receptor in breast cancer [J]. Cancer Biol Ther, 2009, 8(13): 1265-1272. [55] Wang T, Ma X, Krausz KW, et al. Role of pregnane X receptor in control of all-trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance [J]. J Pharmacol Exp Ther, 2008, 324(2): 674-684. [56] Nagaoka R, Iwasaki T, Rokutanda N, et al. Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells [J]. Endocrine, 2006, 30(3): 261-268. [57] Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux [J]. Nat Med, 2001, 7(5): 584-590. [58] Mani S, Huang H, Sundarababu S, et al. Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents [J]. Clin Cancer Res, 2005, 11(17): 6359-6369. [59] Desai PB, Nallani SC, Sane RS, et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen [J]. Drug Metab Dispos, 2002, 30(5): 608-612. [60] Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States [J]. JAMA, 2008, 300(24): 2867-2878. [61] Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability [J]. Br J Clin Pharmacol, 2001, 52(5): 587-595. [62] Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John's wort on irinotecan metabolism [J]. J Natl Cancer Inst, 2002, 94(16): 1247-1249. [63] Huang H, Wang H, Sinz M, et al. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole [J]. Oncogene, 2007, 26(2): 258-268. [64] Ekins S, Chang C, Mani S, et al. Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites [J]. Mol Pharmacol, 2007, 72(3): 592-603. |
[1] | HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831. |
[2] | LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340. |
[3] | PAN Shu, WU Yijin, ZHANG Sasa, WANG Qihai, LUO Tingting, YIN Qin. Pharmacokinetics of methotrexate mediated by organic anion transporter 3 in adjuvant induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 516-525. |
[4] | PENG Juan, FAN Linlin, LI Ranyi, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng. Progress of pharmacotherapy for heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 373-381. |
[5] | CHEN Jiayin, WANG Li, WANG Lijun, TONG Gangling, MA Jie, CHEN Xijing, LU Yang. Correlation between organic cation transporter gene polymorphisms and the toxicities and clinical response of oxaliplatin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 171-177. |
[6] | LIU Lu, CHEN Xiaoyan. Current status of clinical drug-drug interactions research of innovative small molecule drugs in China [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 863-875. |
[7] | MENG Qiang, LIU Kexin. Research status and prospect of transporter-mediated drug-drug interactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 876-888. |
[8] | ZHOU Han, LIU Xiaodong. Application of physiologically based pharmacokinetic model in drug development and several questions being thought [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 889-913. |
[9] | ZHANG Yuanjin, HUANG Shengbo, LIU Jie, WANG Xin. Construction and application of innovation gene-edited rats and intestinal 3D organoids models in drug metabolism and pharmacokinetics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 914-922. |
[10] | LU Qiong, ZHU Haihong, QI Tingting, LI Guohua, TENG Xinqi, QU Qiang, QU Jian. OCTN2 gene polymorphisms affect the chemotherapeutic sensitivity of oxaliplatin in colorectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 401-407. |
[11] | ZHONG Kailong, WANG Yongsheng, CHEN Fang, YE Yanrong. Exploration and expectation on treatment strategies of central nervous system diseases based on transporters at blood-brain barrier [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 953-960. |
[12] | LI Danyun, NIU Peiguang, SHI Daohua. Advances in antitumor drugs based on glutamine metabolism#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 810-816. |
[13] | SHA Bijun, ZHOU Sufeng, WANG Lu, ZHAO Yuqing, CHEN Xijing, SHAO Feng. Methods and progress of clinical research on drug-drug interactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1037-1045. |
[14] | LIN Min, SHEN Zhongxia, QIAN Mincai, CUI Lijun, REN Lie, CAI Min, SHEN Xinhua. Relationship between 5-HTT gene polymorphism and treatment response in the treatment of generalized anxiety disorder patients with anti-depressants [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 903-909. |
[15] | CHEN Hongzhu, LIU Jianming, ZHOU Fang, JIA Yuanwei, WANG Guangji, ZHANG Jingwei. Effect and mechanism of endogenous metabolism on drug metabolism and disposition [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 580-588. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||